Recombination activating 2 (RAG2) (RAG2)

Recombination activating 2 (RAG2) is a critical protein that, in partnership with RAG1, forms the RAG endonuclease complex required for V(D)J recombination in developing lymphocytes [1, 2]. This site-specific recombination process is essential for generating the vast diversity of T-cell receptors and immunoglobulins necessary for a functional adaptive immune system [4]. RAG2 functions by binding to trimethylated histone H3 lysine 4 (H3K4me3), which directs the RAG complex to specific chromatin regions and enhances the DNA-cleavage activity of RAG1 [1, 4]. Mutations in the RAG2 gene lead to various forms of primary immunodeficiency, most notably autosomal recessive severe combined immunodeficiency (SCID) and Omenn syndrome, which are life-threatening without treatment such as hematopoietic stem cell transplantation or experimental gene therapy [3]. Furthermore, dysregulated RAG2 expression or activity is associated with chromosomal translocations that drive lymphoid malignancies like leukemia and lymphoma [4]. While RAG2 is not currently a target for conventional small-molecule drugs, it remains a primary target for genetic correction and a subject of intense study in oncology and immunology [3].

Other names

Recombination activating gene 2RAG-2V(D)J recombination-activating protein 2

There are no approved small-molecule drugs targeting RAG2; however, therapeutic approaches such as gene therapy aim to restore functional RAG2 expression to enable proper V(D)J recombination and lymphocyte development [3].